Lv2
150 积分 2024-09-06 加入
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
2个月前
已完结
Clinical Impact of Hepatic Impairment on the Pharmacokinetics of Sotorasib and Its Major Metabolites: Implications for Dose Adjustment
2个月前
已完结
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
3个月前
已完结
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas
3个月前
已完结
Sotorasib nel carcinoma polmonare non a piccole cellule con mutazione KRAS G12C: dall’evidenza alla pratica clinica
4个月前
已完结
Single Agent VS-6766 or VS-6766 Plus Defactinib in KRAS -Mutant Non-Small-Cell Lung Cancer: The RAMP-202 Phase II Trial
5个月前
已完结
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
5个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
6个月前
已完结
Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA adverse event reporting system
6个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
8个月前
已完结
皖公网安备34019202002308
